Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG2451 and GLPG2451/Galicaftor in Healthy Males
NCT03214614Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG2451 and galicaftor in cystic fibrosis (CF) (4 arms), sponsored by Galapagos NV. Primary endpoint: Change versus placebo in the proportion of subjects with adverse events. Started Nov 2016; status: completed.
02
Drugs
GLPG2451galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03214614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03214614.